Eli Lilly and Company





Market Closed - Nyse 04:00:02 2024-07-19 pm EDT 5-day change 1st Jan Change
857.5 USD +1.01% Intraday chart for Eli Lilly and Company -9.59% +47.10%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Wall St extends slump after global tech glitch, S&P 500, Nasdaq headed for weekly losses RE
Eli Lilly's weight loss drug tirzepatide gets approval in China RE
Wall Street wobbles amid global outage Our Logo
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Eli Lilly's Mounjaro Gets Approval in China for Weight Management MT
Eli Lilly's Mounjaro Approved for Weight Loss in China MT
HSBC Raises Price Target on Eli Lilly to $1,100 From $880, Maintains Buy Rating MT
ANALYST RECOMMENDATIONS : Bank of America, Pepsico, Apple, Chewy, Eli Lilly... Our Logo
Eli Lilly's weight loss drug tirzepatide gets approval in China RE
Health Care Drops as Novo Nordisk, Eli Lilly Slide - Health Care Roundup DJ
Wall Street falls as investors look beyond megacap shares RE
Global markets live: Adidas, TSMC, Vale, HSBC, J&J... Our Logo
Stocks to watch as Biden, Trump vie for presidency RE
TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850 MT
Earnings reports take center stage as tech stocks tumble Our Logo
Wall Street set to fall as megacap chip, tech stocks tumble RE
ANALYST RECOMMENDATIONS : American Airlines, Chevron, UnitedHealth, Bank of America, Eli Lilly... Our Logo
Roche reports positive early results in obesity drug trial RE
Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793 MT
Novo owner backs Swiss biotech Asceneuron in $100 million round RE
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market RE
Ozempic linked with lower dementia risk, nicotine use, British study finds RE
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns MT
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating MT
Chart Eli Lilly and Company
More charts
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
857.5 USD
Average target price
909.9 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. Eli Lilly Gets FDA Approval for Selpercatinib to Treat Thyroid Cancer